We've found
17,819
archived clinical trials in
Brain Cancer
We've found
17,819
archived clinical trials in
Brain Cancer
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Updated: 7/20/2016
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Click here to add this to my saved trials

Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
Updated: 7/21/2016
CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors
Status: Enrolling
Updated: 7/21/2016
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
Updated: 7/21/2016
CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors
Status: Enrolling
Updated: 7/21/2016
Click here to add this to my saved trials

Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
Updated: 7/21/2016
CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors
Status: Enrolling
Updated: 7/21/2016
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
Updated: 7/21/2016
CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors
Status: Enrolling
Updated: 7/21/2016
Click here to add this to my saved trials

Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
Updated: 7/21/2016
CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors
Status: Enrolling
Updated: 7/21/2016
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
Updated: 7/21/2016
CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors
Status: Enrolling
Updated: 7/21/2016
Click here to add this to my saved trials

DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Updated: 7/25/2016
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated: 7/25/2016
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Updated: 7/25/2016
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated: 7/25/2016
Click here to add this to my saved trials

DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Updated: 7/25/2016
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated: 7/25/2016
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Updated: 7/25/2016
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated: 7/25/2016
Click here to add this to my saved trials

DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Updated: 7/25/2016
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated: 7/25/2016
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Updated: 7/25/2016
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated: 7/25/2016
Click here to add this to my saved trials

Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
Updated: 7/25/2016
Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Survivin-Positive Malignant Gliomas
Status: Enrolling
Updated: 7/25/2016
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
Updated: 7/25/2016
Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Survivin-Positive Malignant Gliomas
Status: Enrolling
Updated: 7/25/2016
Click here to add this to my saved trials

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Updated: 7/25/2016
A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors
Status: Enrolling
Updated: 7/25/2016
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Updated: 7/25/2016
A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors
Status: Enrolling
Updated: 7/25/2016
Click here to add this to my saved trials

Electronic Medical Record Review in Monitoring the Effects of Adherence on Myelosuppression and Morbidity in Patients With Newly Diagnosed Brain Tumors Receiving Temozolomide and Radiation Therapy
Updated: 7/26/2016
Evaluation of a Data Driven System for Insuring Timely Monitoring for Brain Tumor Patients for Management of Myelosuppression
Status: Enrolling
Updated: 7/26/2016
Electronic Medical Record Review in Monitoring the Effects of Adherence on Myelosuppression and Morbidity in Patients With Newly Diagnosed Brain Tumors Receiving Temozolomide and Radiation Therapy
Updated: 7/26/2016
Evaluation of a Data Driven System for Insuring Timely Monitoring for Brain Tumor Patients for Management of Myelosuppression
Status: Enrolling
Updated: 7/26/2016
Click here to add this to my saved trials

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
Updated: 8/1/2016
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated: 8/1/2016
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
Updated: 8/1/2016
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
Updated: 8/1/2016
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated: 8/1/2016
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
Updated: 8/1/2016
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
Updated: 8/1/2016
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated: 8/1/2016
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
Updated: 8/1/2016
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
Updated: 8/1/2016
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated: 8/1/2016
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
Updated: 8/1/2016
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
Updated: 8/1/2016
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated: 8/1/2016
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
Updated: 8/1/2016
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials

Information Presentation Formats
Updated: 8/1/2016
Information Presentation Formats and Pursuit of Diagnostic Information
Status: Enrolling
Updated: 8/1/2016
Information Presentation Formats
Updated: 8/1/2016
Information Presentation Formats and Pursuit of Diagnostic Information
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Click here to add this to my saved trials

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Click here to add this to my saved trials

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Click here to add this to my saved trials

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Click here to add this to my saved trials

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Click here to add this to my saved trials

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Click here to add this to my saved trials

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Click here to add this to my saved trials

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Click here to add this to my saved trials

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Click here to add this to my saved trials

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Click here to add this to my saved trials

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Click here to add this to my saved trials

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Click here to add this to my saved trials

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Updated: 8/11/2016
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Click here to add this to my saved trials
